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Original article
Evaluation of changes in random blood glucose and 
body mass index during and after completion of 
chemotherapy in children with acute lymphoblastic 
leukemia
Purpose: Improved survival of patients with childhood acute 
lymphoblastic leukemia (ALL) has drawn attention to the potential 
for late consequences of previous treatments among survivors, 
including metabolic syndrome. In this study, we evaluated changes 
in 3 parameters, namely, random blood glucose, body mass index 
(BMI), and Z score for BMI (Z-BMI), in children with ALL during 
chemotherapy and after completion of treatment. 
Methods: Patients newly diagnosed with ALL from January, 2005 to 
December, 2008 at Saint Mary’s Hospital, The Catholic University 
of Korea, who completed treatment with chemotherapy only were 
included (n=107). Random glucose, BMI, and Z-BMI were recorded at 
5 intervals: at diagnosis, before maintenance treatment, at completion 
of maintenance treatment, and 6 and 12 months after completion 
of maintenance treatment. Similar analyses were conducted on 2 
subcohorts based on ALL risk groups.
Results: For random glucose, a paired comparison showed significantly 
lower levels at 12 months post-treatment compared to those at initial 
diagnosis (P<0.001) and before maintenance (P<0.001). The Z-BMI 
score was significantly higher before maintenance than at diagnosis 
(P<0.001), but decreased significantly at the end of treatment (P<0.001) 
and remained low at 6 months (P<0.001) and 12 months (P<0.001) 
post-treatment. Similar results were obtained upon analysis of risk 
group-based subcohorts.
Conclusion: For a cohort of ALL patients treated without allogeneic 
transplantation or cranial irradiation, decrease in random glucose and 
Z-BMI after completion of chemotherapy does not indicate future 
glucose intolerance or obesity.
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Introduction
With the overall survival of childhood acute lymphoblastic 
leukemia (ALL) surpassing 80%, much attention is now focused on 
minimizing the long-term adverse effects of necessary treatment. An 
important disease entity in this regard, is the aggregate of obesity, 
impaired glucose tolerance and insulin resistance, dyslipidemia, 
and hypertension that comprise the metabolic syndrome. First 
described by Reaven
1) in 1988, the metabolic syndrome is now a well-
established disease of adulthood and is known to increase the risk of 
cardiovascular events and subsequent mortality
2).
Several reports have previously shown that adult survivors of 
childhood ALL are at increased risk of developing the metabolic 
syndrome
3,4), with more recent studies indicating an overall 
prevalence of 9 to 13% amongst adults survivors
5,6). These rates are 
significantly higher than are found in the control adult population. 
Important risk factors that have become evident from these studies 
include the use of cranial irradiation for central nervous system 
(CNS) prophylaxis
7,8), and treatment with total body irradiation as 
part of the conditioning regimen before allogeneic hematopoietic 
stem cell transplantation (HSCT)
5). Growth hormone deficiency 
that can result from both of these treatment modalities is a significant 
causative factor for the development of metabolic syndrome, 
and growth hormone replacement may allow for amelioration of 
metabolic syndrome indices
9).
However, the number of children who have been exposed to 
either of these 2 significant treatment modalities amongst those who 
have recently completed treatment for ALL is small. HSCT is not 
undertaken on the majority of patients with childhood ALL, and 
with greater emphasis on intensive intrathecal treatment as the means 
of CNS prophylaxis in recent treatment regimens, the number of 
patients administered cranial irradiation is decreasing.  Hence, the 
question arises as to whether the increased risk of metabolic syndrome 
observed in adulthood is still applicable to the majority of children 
who have recently completed treatment for ALL.
To address this issue, in this study we observed for changes in 2 
significant parameters of the metabolic syndrome, random blood 
glucose and body mass index (BMI), both crude BMI and age and 
gender-adjusted Z score for BMI (Z-BMI), in a cohort of children 
who have recently completed treatment for ALL with chemotherapy 
only, without either cranial irradiation or HSCT.
Materials and methods
1. Study cohort
Initial study cohort consisted of 164 children newly diagnosed with 
ALL during a 4 year period from January, 2005 to December, 2008 
at the Department of Pediatrics, Saint Mary’s Hospital, The Catholic 
University of Korea.
In order to study a uniform group of patients who had completed 
sequential ALL chemotherapy without event and were currently 
off treatment, the following exclusions were made: 1) patients who 
experienced an event: 9 relapsed patients, 4 patients who died without 
achieving first complete remission, 2) patients who received treatment 
other than risk group-based sequential chemotherapy: 26 patients 
who received allogeneic HSCT at any point in treatment, 2 patients 
who underwent major modifications to the chemotherapy regimen 
due to toxicity, 3) patients with incomplete data or follow-up till end 
of chemotherapy: 5 patients who were transferred to other institutions 
before completion of treatment, 2 patients with incomplete data, 
and 9 patients who were still receiving chemotherapy as of May 31st, 
2011. Hence, the final study cohort included 107 ALL patients who 
had completed chemotherapy without event (Table 1).
2. Treatment for ALL
Newly diagnosed patients were stratified into four risk groups 
according to a classification scheme that has been published 
previously
10), incorporating major characteristics at diagnosis as well 
as response to initial treatment. Chemotherapy was done according 
to institutional protocol (CMCPL-2005), with remission induction 
undertaken as published elsewhere
11). Chemotherapy following 
the consolidation phase differed according to risk group with low 
and standard risk patients treated with only one phase of interim 
maintenance and delayed intensification each before entering 
Table 1. Major Characteristics of the Study Cohort
Characteristics Value
Age (yr)  5.2 (0.9–16.2)
Gender
  Male / Female 55 (51) / 52 (49)
Initial WBC count (/mm
3) 12,690 (1,010–515,910)
Immunophenotype
  B / T / mixed 94 (88) / 9 (8) / 4 (4)
Overall risk group
  Low / standard 25 (23) / 32 (30)
  High / very high 31 (29) / 19 (18)
Cytogenetics
  t(12;21) / t(1;19) 26 (24) / 11 (10)
  t(9;22) / MLL rearrangement 1 (1) / 3 (3)
  Hyperdiploidy / others / normal 20 (19) / 38 (36) / 8 (8)
Values are presented as median (range) or number (%).
WBC, white blood cell; B, precursor B cell; T, T cell; MLL, mixed-lineage 
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maintenance, while high and very high risk patients underwent two 
phases of interim maintenance and delayed intensification. CNS 
prophylaxis consisted of sequential intrathecal chemotherapy and did 
not include CNS irradiation. Low-standard risk patients received 19 
to 21 doses of intrathecal chemotherapy throughout treatment, while 
high-very high risk patients received 25 to 28 doses. Maintenance 
treatment included 8 cycles of chemotherapy administered every 12 
weeks. Throughout treatment, dexamethasone was administered for 
steroid treatment. After completion of treatment, patients underwent 
regular follow-up in the outpatient clinic to check status, including 
measurements of weight and height, complete blood counts and 
blood chemistry values.
3. Study design
1) Data collection
In order to study significant changes in random glucose, BMI, 
and Z-BMI, these values were retrospectively reviewed and recorded 
for five specific clinical points for the patients in the study cohort: 
at diagnosis, just before start of maintenance chemotherapy, at 
completion of maintenance chemotherapy, 6 months after com-
pletion of chemotherapy, and 12 months after completion of 
chemotherapy (Fig. 1). These time points were chosen to observe 
changes in the study parameters from diagnosis to completion 
of intensive sequential chemotherapy (time point before start of 
maintenance chemotherapy), to completion of treatment. Random 
glucose values were obtained from blood chemistry results. BMI was 
calculated from the formula: BMI=weight (kg) / (height [m])
2.
Z-BMI was calculated utilizing age and gender appropriate L, M, 
S  values and methods previously published on recent growth indices 
in Korean children
12). For the purposes of evaluation, Z-BMI>2 
was considered overweight, and BMI≥25 kg/m
2 or Z-BMI>3 was 
considered obese. Depending on the date of treatment completion, 
not all the patients in the study cohort had data for up till 1 year 
after end of treatment; overall, 107, 92, and 88 patients had values 
for up till completion of maintenance chemotherapy, 6 months after 
completion of chemotherapy, and 12 months after completion of 
chemotherapy respectively.
2) Data analysis
Initially, the mean values for random glucose, BMI and Z-BMI 
were compared according to time point after treatment completion. 
Hence, the mean values at diagnosis and before initiation of 
maintenance chemotherapy were compared to those at completion 
of maintenance treatment (n=107), 6 months after treatment 
completion (n=92), and 12 months after treatment completion (n=88) 
respectively. Analysis was done to observe for significant trends in 
mean values obtained from the three sequential time points.
Second, in order to retrieve results from a uniform cohort with 
complete data, mean values for the three study parameters were 
calculated and compared for all five time points for the 88 patients 
who had complete follow-up data up till one year after treatment 
completion. After observing for overall significant trends, the 
following specific, paired comparisons of mean values were made; 
1) at diagnosis – before maintenance  2) at diagnosis – 12 months 
after treatment completion  3) before maintenance – at treatment 
completion  4) before maintenance – 6 months after treatment 
completion  5) before maintenance – 12 months after treatment 
completion.
Finally, the full cohort of 88 patients was divided into 2 sub-cohorts 
based on ALL risk group: low/standard risk group (41 patients) and 
high/very high risk group (47 patients).  Similar analyses of overall 
trends in the measurements at 5 time points, and paired comparisons 
as had been done for the full cohort of 88 patients were done on these 
2 separate cohorts. 
4. Statistical analysis
Mean values and standard errors of the mean were calculated 
for each study parameter.  In order to observe for overall significant 
trends in the mean values at sequential time points, one-way repeated-
measures analysis of variance (ANOVA) was used.  Assumption 
of sphericity was tested using Mauchly’s test.  If the assumption of 
sphericity was violated, multivariate ANOVA (MANOVA) testing 
was done, with Pillai’s trace statistic considered for test significance. 
Pairwise comparisons within the framework of multiple repeated 
5 4 3
Pre-maintenance
chemotherapy
Maintenance
chemotherapy
Follow-up after
treatment completion
1 2
Post-6 
months
Post-12 
months
Fig. 1. Schematic of patient chemotherapy, follow-up after completion 
of chemotherapy, and time points of data collection. (1) The arrows 
with Arabic numerals indicate time points of data collection: 1, at 
diagnosis; 2, just before the start of maintenance chemotherapy; 3, at 
completion of maintenance chemotherapy; 4, 6 months after completion 
of chemotherapy; 5, 12 months after completion of chemotherapy. 
(2) The period of premaintenance chemotherapy includes remission 
induction, consolidation, sequential interim maintenance, and delayed 
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time points after treatment completion, that is, at completion of 
maintenance, 6 months and 12 months after treatment completion. 
A significant difference in the study parameter values at the 3 time 
points was found for all instances except for random glucose at 
diagnosis – before maintenance – treatment completion. 
For random glucose, there was a significant trend towards lower 
values at 6 months and 12 months after treatment completion 
compared to values both at diagnosis and before maintenance 
treatment. For both BMI and Z-BMI, there was a significant trend 
towards higher values at all points after treatment completion 
compared to those at initial diagnosis.  However, the values observed 
post-treatment tended to be lower than the peak values observed 
measures were done with paired t-tests, with Bonferroni correction 
done for the five comparisons. P value of <0.05 was considered 
significant. Statistical analyses were done with SAS ver. 9.1 (SAS 
Institute Inc., Cary, NC, USA) and SPSS ver. 12 (SPSS Inc., Chicago, 
IL, USA).
 Results
1. Analysis according to time point after treatment 
completion
Table 2 summarize the values for random glucose, BMI, and 
Z-BMI at diagnosis, before maintenance treatment, and the 3 
Table 2. Mean Values for Random Glucose, BMI and Z-BMI
At completion of maintenance treatment 
(n=107)
6 Months after the completion of treatment 
(n=92)
12 Months after the completion of treatment 
(n=88)
At 
diagnosis
Before 
maintenance
At completion 
of maintenance
P 
value*
At 
diagnosis
Before 
maintenance
6 Months               
post-
completion
P 
value*
At 
diagnosis
Before 
maintenance
12 Months             
post-
completion
P 
value*
Glucose 
(mg/dL)
110.8±2.5 113.1±2.1 109.4±2.4 0.507 108.9±2.8 112.9±2.3 93.2±1.9 <0.001 107.6±2.7 113.3±2.3 92.9±1.1 <0.001
BMI 
(kg/m
2)
17.3±0.3 19.5±0.3 19.7±0.4 <0.001 17.1±0.3 19.3±0.3 18.9±0.3 <0.001 17.1±0.3 19.4±0.3 19.0±0.3 <0.001
Z-BMI 0.11±0.10 1.09±0.11 0.72±0.12 <0.001 0.04±0.11 1.05±0.12 0.35±0.12 <0.001 0.04±0.11 1.06±0.12 0.33±0.11 <0.001
Values are presented as mean ±standard error.
BMI, body mass index; Z-BMI, age and gender-adjusted Z score for BMI.
*P  values were obtained from either one-way repeated-measures analysis of variance (ANOVA) or multivariate ANOVA with the assumption of no significant 
difference in the value at the 3 time points as the null hypothesis.
Table 3. Mean Values for Random Glucose, BMI, and Z-BMI at all 5 Time Points for the Full Cohort of 88 Patients up to 12 Months after the 
Completion of Treatment
At diagnosis Before maintenance At completion of maintenance 6 Months post-completion 12 Months post-completion P value*
Glucose (mg/dL) 107.6±2.7 113.3±2.3 107.6±2.7 93.3±1.9 92.9±1.1 <0.001
BMI (kg/m
2) 17.1±0.3 19.4±0.3 19.5±0.4 18.9±0.3 19.1±0.3 <0.001
Z-BMI 0.06±0.11 1.06±0.12 0.65±0.14 0.34±0.12 0.34±0.11 <0.001
Values are presented as mean±standard error.
BMI, body mass index; Z-BMI, age and gender-adjusted Z score for BMI.
*P values were obtained from multivariate analysis of variance with the assumption of no significant difference in the values at the 3 time points as the null 
hypothesis.
Table 4. Paired Comparisons within the Uniform Cohort (n=88) for Random Glucose, Body Mass Index (BMI), and Z-BMI Measured at the 5 
Consecutive Time Points
Glucose BMI Z-BMI
Mean 
difference
Standard 
deviation
P 
value*
Mean 
difference
Standard 
deviation
P
value*
Mean 
difference
Standard 
deviation
P
value*
(Before maintenance) –  (at diagnosis) 5.7 29.5 0.365 2.2 2.3 <0.001 1.00 1.0 <0.001
(At 12 months post-treatment completion) – (at diagnosis) -14.7 26.9 <0.001 1.9 2.6 <0.001 0.28 1.0 0.040
(At treatment completion) – (before maintenance) -5.7 32.9 0.550 0.1 2.1 1.000 -0.41 0.9 <0.001
(At 6 months post-treatment completion) – (before maintenance) -20.0 29.7 <0.001 -0.5 2.0 0.120 -0.72 0.8 <0.001
(At 12 months post-treatment completion) – (before maintenance) -20.4 24.0 <0.001 -0.3 2.4 1.000 -0.72 0.0 <0.001
*P values obtained from paired t test and corrected for the number of in-group comparisons, that is 5, according to Bonferroni procedure.Korean J Pediatr 2012;55(4):121-127 • http://dx.doi.org/10.3345/kjp.2012.55.4.121    125
before maintenance treatment.
2. Analysis of uniform cohort of patients up till 12 months 
after treatment completion
Table 3 and Fig. 2A–C show the mean values for random glucose, 
BMI, and Z-BMI at all 5 time points for a full cohort of 88 patients 
up till 12 months after treatment completion. A significant difference 
was found in the measurement of all 3 study parameters for the 5 
consecutive time points (P<0.001 for each parameter).
For random glucose, the mean value at 12 months post-treatment 
completion was significantly lower than that at diagnosis (Table 4). 
Furthermore, the mean values at 6 months and 12 months post-
treatment completion were significantly lower than that before 
maintenance treatment, that is after having completed intensive 
sequential chemotherapy.  The highest random glucose level was 
measured before maintenance treatment (Fig. 2A).  At 12 months 
post-treatment completion, none of the patients had random glucose 
values suggestive of impaired glucose tolerance.
For BMI, the mean values before maintenance treatment and at 12 
months post-treatment completion were significantly higher than the 
mean BMI at diagnosis.
For Z-BMI, again the mean values before maintenance treatment 
and at 12 months post-treatment completion were significantly 
higher than the mean Z-BMI at diagnosis. However, unlike the crude 
measurement of BMI, Z-BMI decreased significantly at treatment 
completion and at 6 and 12 months post-treatment completion 
compared to the mean value before maintenance treatment. The 
highest Z-BMI was measured before maintenance treatment (Fig. 
2C). At 12 months post-treatment completion, 5 patients (5.7%) had 
Z-BMI values indicative of overweight status (Z-BMI>2), and none 
had values consistent with obesity.
3. Analysis of 2 subcohorts based on ALL risk group up till 
12 months after treatment completion
A similar study of mean values for random glucose, BMI and Z- 
BMI at all 5 time points was done separately on 2 subcohorts based 
on ALL risk group. Again, significant differences were found in the 
consecutive measurements of the study parameters for the 5 time 
points, despite dividing the cohort based on risk group (P<0.001 for 
each parameter).  
Paired analyses done for each subcohort showed similar results 
as for the full cohort for random glucose and BMI (Fig. 2A, B). 
However, for random glucose, the mean value before the beginning 
of maintenance treatment was significantly higher than at diagnosis 
for the high-very high risk subcohort (P=0.008). The highest random 
glucose measurement was checked at diagnosis for the low-standard 
risk group, with decreasing values throughout chemotherapy 
and completion. For the high-very high risk group, the highest 
measurement was checked before maintenance treatment, similar to 
results for the full cohort (Fig. 2A).
Paired analyses for Z-BMI showed the same results as for the full 
cohort except in 2 instances; for the low-standard risk subcohort, 
the value at 12 months post-completion, although higher, did not 
differ significantly from that at diagnosis (P=1.000). For Z-BMI, the 
highest level was checked before maintenance treatment for the low-
standard risk group, as was the case for the full cohort. However, for 
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Fig. 2. Mean values for random glucose (A), body mass index (BMI) (B), 
Z score for BMI (Z-BMI) (C) at all 5 time points for the full cohort of 88 
patients up to 12 months after the completion of treatment (bold line), 
as well as for subcohorts of low-standard risk patients (dashed line) and 
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the high-very high risk group the Z-BMI increased from diagnosis up 
till treatment completion, gradually decreasing afterwards (Fig. 2C).
Discussion
In this study, we evaluated for changes in random glucose and 
BMI during and immediately after treatment for childhood ALL. 
These 2 values are important components for the diagnosis of 
metabolic syndrome which, in the context of treatment for childhood 
ALL, may be caused by growth hormone deficiency or endothelial 
dysfunction after chemotherapy
13). With most reports of a linkage 
between treatment for childhood ALL and the metabolic syndrome 
originating from North America and Europe, we believe our study is 
one of the few that derive from a non-Western pediatric population.
In our study of a full cohort of 88 patients, as well as the study of 
subcohorts based on risk group, we found significant differences 
in the consecutive values of random glucose, BMI and Z-BMI 
measured at 5 different time points. Several important observations 
could be made with regards to random glucose trends. First, the 
random glucose measurement was highest before beginning of 
maintenance treatment, that is after having completed sequential 
intensive chemotherapy including remission induction, consolidation 
and delayed intensification. However, the mean random glucose level 
even at this highest point was not indicative of glucose intolerance, 
bringing to question the actual impact of chemotherapy on hyper-
glycemia. Also, a significant difference between mean random 
glucose at this time point and mean random glucose at diagnosis 
was only observed in the high-very high risk group subcohort, 
possibly indicating a greater effect of more prolonged chemotherapy 
in this group on blood glucose level. Second, this peak of random 
glucose level decreased significantly at 6 months and 12 months after 
treatment completion to normal levels, in accordance with a previous 
study which found no relationship between transient hyperglycemia 
during treatment and glucose intolerance in the first several years 
after treatment completion
14). Third, the random glucose levels after 
treatment completion were even lower than those found at diagnosis 
and for the low-standard risk subcohort, the mean random glucose at 
diagnosis was actually the highest point in overall follow-up. Several 
studies have noted an increased incidence of transient hyperglycemia 
during remission induction treatment for childhood ALL
15,16), mostly 
with an emphasis on chemotherapy-related etiology. However, our 
results, especially those of the low-standard risk subcohort emphasize 
the possible role of baseline disease status prior to treatment, and the 
catabolic effect of a physically stressed situation at diagnosis as having 
a major impact on hyperglycemia prior to remission induction.
The mean BMI predictably increased from diagnosis to before 
maintenance treatment, and seemed to plateau afterwards. However, 
none of the mean BMI values at the 5 time points fulfilled the de-
finition of either overweight status or obesity.
The 50th percentile BMI value tends to show a normal increase 
with age, and in order to correct for this physiologic incrementation 
we also analyzed for age and gender-adjusted BMI Z score. Important 
points that could be summarized from analysis of Z-BMI data were as 
follows: first, as was the case with random glucose, the mean Z-BMI 
value for the full cohort peaked at the beginning of maintenance 
treatment, again possibly emphasizing the effect of sequential 
intensive chemotherapy on metabolic syndrome indices. Second, the 
high mean Z-BMI tended to decrease during maintenance treatment 
and was significantly lower at treatment completion, as well as 6 
and 12 months afterwards. Third, although the mean value at 12 
months post-treatment completion was lower than the peak before 
maintenance treatment, it was still significantly higher than the mean 
Z-BMI found at diagnosis for the full cohort and the high-very high 
risk subcohort, indicating the need for continued monitoring for 
obesity beyond 12 months post-treatment completion.
In summary, then, although both the random glucose level 
and the Z-BMI peaked after completion of intensive, sequential 
chemotherapy, none of the mean values were high enough to indicate 
a disease process such as glucose intolerance or obesity. Furthermore, 
these values declined significantly from this peak after completion 
of treatment and during the short 12 month follow-up that ensued, 
although the mean Z-BMI was still higher at last follow-up than 
at diagnosis. The potential for late-onset metabolic syndrome still 
exists, demanding long-term follow-up into adulthood, but the risk 
for metabolic syndrome, at least in terms of glucose intolerance and 
obesity, is not fully evident in our short-term follow-up of patients 
naïve to both cranial irradiation and HSCT.  
These results are in contrast to those of similar studies of obesity 
in childhood ALL patients who completed treatment with chemo-
therapy only, in which a significant portion of patients studied were 
found to be either overweight or obese at treatment completion
17,18). 
One previous study also based on Korean children with ALL found 
a trend towards continued increase in BMI even after treatment 
completion
19).
Our study also brings to question the risk for late-onset metabolic 
syndrome for the majority of current childhood ALL patients who 
receive chemotherapy only for treatment. Recent longitudinal studies 
on metabolic syndrome in survivors of childhood ALL were done 
on adults with a median age at evaluation of 21.2 and 28 years
5,6). 
Hence, many of these adults were treated with previous ALL re-
gimens with incorporation of cranial irradiation. The projected 
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completed treatment, such as the cohort in this study, may differ 
significantly from current estimations. Possibly even, the increased 
risk for metabolic syndrome for the majority of ALL survivors may 
be limited to people belonging to certain historical cohorts treated on 
past regimens, and who are now adults, and may differ in survivors 
who are now still children and require long-term follow-up into 
adulthood. The role of underlying ethnic differences in childhood 
and adult incidence of obesity and metabolic syndrome also requires 
evaluation when considering disparities between our results and past 
analyses that derive mostly from non-Asian nations
20).
In conclusion, our short-term follow-up of 2 major indices of the 
metabolic syndrome, blood random glucose and BMI, in children 
who have completed treatment for ALL with chemotherapy only 
indicates transient rises to non-pathologic levels for both factors 
after intensive chemotherapy, with subsequent decline, rather than 
persistent elevation, after treatment completion. As metabolic 
syndrome is defined by more than just glucose levels and BMI, 
potential for increased risk of metabolic syndrome with maturation 
of our cohort into adulthood requires further investigation. However, 
this short-term analysis does not hint at a greater risk for either future 
glucose intolerance or obesity for these children.
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